ArticleInternational journal of breast cancer2026
Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status.
Article in International journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating delta radiomics and changes in multimodal ultrasound features for predicting response to neoadjuvant chemotherapy in breast cancer.Gland surgery · 2026Article
- Article
- Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status.International journal of breast cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify predictive factors of pathological complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC), and to establish a "clinical-imaging-molecular" three-dimensional evaluation model to guide clinical decision-making. Methods: A retrospective study was conducted on 55 breast cancer patients who underwent NAC at Nanyang Second People's Hospital from January 2023 to August 2024. Collected data included demographic variables (age, BMI, and menstrual status), tumor characteristics (tumor size, axillary lymph node [N] stage, histological grade, color Doppler ultrasound features including blood flow signal [CDFI], morphology, and aspect ratio), molecular markers (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor-2 [HER-2], and Ki-67), and treatment-related factors (chemotherapy regimen). Univariate analyses (Pearson's chi-square test or Fisher's exact test) were initially conducted to screen variables potentially associated with pCR ( Results: The overall pCR rate was 36.4% (20/55). Among molecular subtypes, HER-2-positive patients (40.0% of the cohort) had the highest pCR rate (73.0%, 16/22), followed by triple-negative breast cancer (TNBC) patients (15.0% of the cohort, 50.0%, 4/8). Univariate analysis showed that N stage, chemotherapy regimen, Ki-67 index, ER status, PR status, and HER-2 status were significantly correlated with pCR (all Conclusion: pCR rates in breast cancer patients post-NAC vary significantly by molecular subtype. ER negativity and HER-2 positivity emerge as independent predictive factors for pCR, with ER and HER-2 exhibiting the strongest discriminative ability (AUC > 0.8). Clinicians should integrate patients' baseline clinical data, ultrasound features, and molecular markers to screen optimal NAC candidates and develop individualized strategies, thereby maximizing therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.